+113.2%
WDC vs MRNA
+945.0%
-831.8%
-56.6%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 1y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | -6.8% | +13.1% | -19.9% | -6.8% |
| 7D | -18.3% | +20.6% | -39.0% | -18.4% |
| 30D | -26.7% | +27.1% | -53.8% | -26.7% |
| 3M | -40.9% | +353.4% | -394.3% | -42.3% |
| 6M | -26.8% | +446.3% | -473.0% | -35.5% |
| YTD | +88.2% | +776.2% | -688.0% | +34.7% |
| 1Y | +113.2% | +987.9% | -874.7% | +37.2% |
| All | +113.2% | +945.0% | -831.8% | +37.2% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 1y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
1y analysis · Full analysis span regression · 6 months rolling